Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Core Insights - Nautilus Biotechnology, Inc. reported significant advancements in 2024, including the first quantitative measurement of biological variation in tau proteoforms related to Alzheimer's Disease, and improvements in their proteome analysis platform [2] - The company anticipates a commercial launch of its proteome analysis platform in late 2026, following necessary modifications to reduce technical risks and enhance performance [2][7] Financial Performance - For Q4 2024, operating expenses remained flat at $20.0 million compared to Q4 2023, while total operating expenses for the fiscal year 2024 increased by$5.3 million, or 7%, to $81.5 million due to headcount growth [3] - The net loss for Q4 2024 was$17.6 million, slightly higher than the $17.0 million loss in Q4 2023, and the total net loss for the fiscal year 2024 was$70.8 million, compared to $63.7 million in 2023 [4][13] - As of December 31, 2024, the company had cash, cash equivalents, and investments totaling$206.3 million, which is expected to provide a runway through 2027 [4][8] Operational Outlook - The company plans to maintain operating expenses at or below 2024 levels in 2025, while also announcing a reduction in headcount by approximately 16% to align resources with development goals [7][8] - Nautilus will host a conference call to discuss the financial results and business developments on February 27, 2025 [5]